Coronary Peripheral Articles & Analysis
8 news found
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, and Genesis MedTech Group announced today that they have successfully obtained approval from China’s National Medical Products Administration (NMPA) to market and sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and ...
“As we continue to advance our robotic-assisted platform, the new facility will support our mission to elevate the standard of care and increase access to cutting-edge treatment for coronary artery and neurovascular disease.” The new facility marks the first of 15 new offices or major facility expansions that Siemens Healthineers plans in the U.S. ...
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Steve Parker as Chief Executive Officer. ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance. ...
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Christopher (Chris) Meredith as Chairman of the Board of Directors. ...
Food and Drug Administration (FDA) for new software automation that provides predictable and consistent movements to aid in advanced device manipulation during complex coronary and peripheral procedures. Jean Fajadet, M.D., the co-director of interventional cardiology at Clinique Pasteur in Toulouse, France, performed the first in-human coronary ...
Cardiva Medical, Inc. is a privately held medical device company focused on transforming vascular closure for the benefit of patients, hospitals and physicians in the over 5.5 million catheter-based coronary, peripheral and electrophysiology procedures in the United States that require access site closure each year. ...
In June 2019, Orchestra BioMed also secured a $30 million payment and $5 million equity commitment as the upfront financial components of a global strategic partnership with Terumo Corporation to develop and commercialize Virtue® Sirolimus-Eluting Balloon (SEB), the first and only non-coated sirolimus-eluting angioplasty balloon system, in the percutaneous coronary and ...